Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standardised 5-grass pollen allergen extract is a form of sublingual immunotherapy (SLIT) used to treat grass pollen-induced allergic rhinoconjunctivitis. It consists of extracts from five common types of grass pollens: Sweet Vernal (Anthoxanthum odoratum), Orchard (Dactylis glomerata), Perennial Rye (Lolium perenne), Timothy (Phleum pratense), and Kentucky Blue Grass (Poa pratensis). [1] Administered as drops under the tongue, the treatment works by gradually exposing the immune system to these allergens, which induces immunological tolerance, reduces the allergic response, and alleviates symptoms. [4, 7] The provided clinical trial context mentions ALK-Abelló as the sponsor, which is notable because ALK's primary grass pollen products (Grastek/Grazax) are based on a single grass, whereas the 5-grass mix is more commonly associated with Stallergenes Greer's products like Oralair (a tablet) and Staloral (drops). [3, 14, 20, 24] A recent Phase III trial by ALK, named RHAPSODY, has specifically evaluated a 5-grass-pollen SLIT drop formulation. [12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standardised 5-grass pollen allergen extract.